229 related articles for article (PubMed ID: 24757527)
1. Renal cell carcinoma: how to hit the targets?
Banyra O; Tarchynets M; Shulyak A
Cent European J Urol; 2014; 66(4):394-404. PubMed ID: 24757527
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
3. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
Kamli H; Li L; Gobe GC
Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
[No Abstract] [Full Text] [Related]
4. The prospects of pazopanib in advanced renal cell carcinoma.
Gupta S; Spiess PE
Ther Adv Urol; 2013 Oct; 5(5):223-32. PubMed ID: 24082917
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
6. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
7. Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.
Yalcin S; Lacin S
Cancer Manag Res; 2019; 11():7779-7785. PubMed ID: 31496820
[TBL] [Abstract][Full Text] [Related]
8. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.
Sciarra A; Gentile V; Salciccia S; Alfarone A; Di Silverio F
Rev Recent Clin Trials; 2008 May; 3(2):97-103. PubMed ID: 18474019
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.
Tan X; Liu Y; Hou J; Cao G
Onco Targets Ther; 2015; 8():313-21. PubMed ID: 25674006
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.
Li W; Feng C; Di W; Hong S; Chen H; Ejaz M; Yang Y; Xu TR
Eur J Med Chem; 2020 Aug; 200():112482. PubMed ID: 32492594
[TBL] [Abstract][Full Text] [Related]
11. Targeted-therapy in advanced renal cell carcinoma.
Pirrotta MT; Bernardeschi P; Fiorentini G
Curr Med Chem; 2011; 18(11):1651-7. PubMed ID: 21428882
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
13. Current management of renal cell carcinoma and targeted therapy.
Canda AE; Kirkali Z
Urol J; 2006; 3(1):1-14. PubMed ID: 17590846
[TBL] [Abstract][Full Text] [Related]
14. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
[TBL] [Abstract][Full Text] [Related]
15. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.
McKay RR; Bossé D; Choueiri TK
J Clin Oncol; 2018 Oct; ():JCO2018790253. PubMed ID: 30372392
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
18. mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model.
Spadazzi C; Recine F; Mercatali L; Miserocchi G; Liverani C; De Vita A; Bongiovanni A; Fausti V; Ibrahim T
J Bone Oncol; 2019 Jun; 16():100227. PubMed ID: 30911462
[TBL] [Abstract][Full Text] [Related]
19. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
20. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
